Peptides are incoming!
The Peptide
Moment Is Here.
The FDA has scheduled a landmark advisory committee review for July 23–24, 2026. Seven restricted peptides — including BPC-157 and TB-500 — are on the table. Here's what it means, why it matters, and what Monday Medical members should know right now.
For the first time since the Biden-era FDA restricted over a dozen popular peptides in 2023, the regulatory landscape is shifting. On April 17, 2026, the FDA confirmed it will convene its Pharmacy Compounding Advisory Committee on July 23 and 24 to evaluate whether seven key peptides should be returned to the 503A Bulks List — the framework that allows licensed compounding pharmacies to legally prepare them with a physician's prescription. This is not a rumor. It is a formal federal proceeding, and the outcome could reshape how patients across the country access some of the most promising tools in regenerative and functional medicine.
How We Got Here
Peptides are short chains of amino acids — the same biological building blocks that form hormones like insulin and the GLP-1 agonists in medications like Ozempic and Wegovy. For years, compounding pharmacies legally produced dozens of peptide-based therapies for patients whose physicians prescribed them for recovery, inflammation, metabolic support, cognitive function, and longevity.
That changed abruptly in late 2023, when the FDA moved to designate a large group of popular peptides as "Category 2" bulk drug substances — a classification that effectively prohibited their compounding for human use, citing concerns about immunogenicity, manufacturing impurities, and limited human clinical data. The move sent shockwaves through the functional medicine and integrative health communities. Virtually overnight, patients who had been using these therapies under physician supervision lost access.
"Ozempic is a peptide. Semaglutide, its active ingredient, is a peptide-based compound that mimics the gut hormone GLP-1. The FDA didn't just approve it — it championed it."
— A regulatory inconsistency noted by multiple clinical observersCritics — including HHS Secretary Robert F. Kennedy Jr. — argued the reclassifications were legally improper, pointing out that Category 2 status is only appropriate when there are documented safety concerns, and that most of the affected peptides had long records of clinical use without serious reported harms. In February 2026, Kennedy stated publicly that he is a "big fan" of peptides and asserted the FDA had acted improperly during the previous administration.
On April 15, 2026, Kennedy directed the FDA to move all 12 peptides toward formal advisory committee review. Two days later, the FDA confirmed the July 23–24 meeting date and published the official docket number (FDA-2025-N-6895) for public comment — open through July 22, 2026.
The Seven Peptides Under Review
The July 23–24 meeting is structured across two days, each covering a distinct group of compounds. All seven are being evaluated for potential inclusion on the 503A Bulks List, which would allow licensed compounding pharmacies to legally produce them with a physician's prescription.
A second PCAC meeting is expected before February 2027 to address five additional peptides not covered in July. The FDA's docket remains open for public comment through July 22, 2026.
What This Review Actually Means
- A positive advisory committee recommendation does not mean these peptides become FDA-approved drugs. It means they become eligible for legal compounding — the same framework that governs compounded semaglutide and hormone therapies.
- The advisory committee's recommendation is influential but not binding. The FDA retains final authority and has, under the current administration, occasionally departed from outside panel guidance.
- Even if the committee votes favorably on July 24, regulatory implementation takes additional time. Nothing changes the day after the meeting. Patients should not expect immediate access.
The Regulatory Path Forward
Compounding pharmacies cease production overnight. Patients on active prescriptions lose access.
During a Joe Rogan podcast, Kennedy states the FDA's reclassifications were legally improper and signals regulatory intent to reverse course.
HHS Secretary formally directs the agency to schedule advisory committee evaluation for all 12 restricted peptides.
Official federal notice published. Docket FDA-2025-N-6895 opens for public comment through July 22, 2026.
Seven peptides reviewed by outside experts. Committee votes and issues recommendation to FDA leadership. Public testimony accepted.
If committee recommends inclusion on 503A Bulks List, FDA must finalize the regulatory change. Timeline varies.
A second round of advisory review covers the remaining peptides from the 2023 restricted list not addressed in July.
The Monday Medical Perspective
We have followed this regulatory story closely — because our members ask about it, and because we believe peptide therapy, when properly prescribed and monitored, represents a meaningful frontier in personalized medicine.
Peptides are not fringe science. They are how your body communicates at the cellular level. Insulin is a peptide. The GLP-1 molecules in some of the most prescribed medications in the country are peptides. The growth hormone-releasing peptides that support lean body mass, sleep quality, and metabolic function are peptides. This category of compounds has been central to human biology since before we had a word for it.
"The question has never really been whether peptides work — it's been whether patients can access them safely, through licensed pharmacies, with physician oversight. That is exactly what the July review could restore."
— Monday Medical Clinical PositionWe also want to be honest about what remains uncertain. The clinical evidence for some of these peptides in humans is still developing. Most of the robust data on compounds like BPC-157 and TB-500 comes from animal models, and while that preclinical evidence is genuinely impressive, it is not the same as large-scale human trials. Our clinical team evaluates each patient individually and will never prescribe something we cannot stand behind clinically.
What We're Watching
Several factors will shape the outcome of the July meeting and the months that follow:
The PCAC currently has vacancies. Kennedy could appoint new members before July, shifting the committee's orientation. Regulatory observers are watching this closely.
The agency is not required to follow the advisory committee's recommendation. Under the current administration, the FDA has occasionally departed from outside expert guidance.
The FDA docket (FDA-2025-N-6895) is open through July 22, 2026. Physicians, patients, and pharmacists can submit formal comments that become part of the official record.
What Monday Medical Members Should Do Now
If you are currently using peptides
If you are a Monday Medical member currently using peptides that have been prescribed by our clinical team, continue your protocol as directed. We are actively monitoring the regulatory situation and will communicate any changes directly to affected members. Your safety and continuity of care is our first priority.
If you've been waiting for peptide therapy
The July meeting is the most encouraging regulatory signal since 2023, but it is not a guarantee and it is not immediate. If you are interested in peptide therapy as part of your wellness protocol, the right time to start the conversation is now — so that if and when access expands, you are already working with a provider who understands your goals, your labs, and your health history.
If you want to engage in the regulatory process
The public comment period for the July PCAC meeting is open through July 22, 2026. Physicians, patients, and practitioners can submit comments to FDA docket FDA-2025-N-6895. Patient experience data, in particular, can be meaningful input when the committee evaluates real-world clinical context. We encourage members with relevant experiences to consider participating.
Regardless of how the July review unfolds, our approach to peptide therapy will not change. We will continue to:
- Prescribe only within legally compliant regulatory frameworks
- Base all recommendations on your individual labs, hormone panel, and clinical profile — not trend cycles or social media momentum
- Work exclusively with accredited, licensed compounding pharmacies that meet rigorous quality standards
- Keep members informed in real time as the regulatory landscape evolves
- Expand our peptide protocols as evidence matures and access becomes available
Ready to Talk Peptides?
Schedule a consultation with a Monday Medical provider and get a personalized assessment of where peptide therapy fits — or doesn't fit — into your protocol.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information reflects current publicly available regulatory developments as of April 21, 2026. Regulatory timelines and outcomes are subject to change. Monday Medical patients should consult directly with their assigned provider regarding any questions about their care plan or access to specific therapies. None of the peptides discussed in this article are FDA-approved for human use; eligibility for compounding is determined by federal regulatory status, which is actively evolving.
Sources: FDA Advisory Committee Calendar (fda.gov), FDA 503A Categories Update April 2026, RAPS, AJMC, BioPharma Dive, American Journal of Managed Care.
